A recent clinical trial has found that taking a daily vitamin D supplement may help improve the effectiveness of chemotherapy in women with breast cancer. The study suggests that a moderate dose of vitamin D can nearly double the chances that chemotherapy will eliminate all detectable cancer before surgery.
Researchers enrolled 80 women aged 45 and older who were diagnosed with breast cancer and scheduled to receive neoadjuvant chemotherapy, a treatment given before surgery to shrink tumors. The participants were randomly assigned to take either 2,000 international units of vitamin D each day or a placebo for six months while they underwent chemotherapy.
The study was based on the fact that breast tissue contains vitamin D receptors. When activated, these receptors can slow tumor growth and promote cancer cell death. Vitamin D also influences immune function and other cellular processes linked to cancer progression.
After completing chemotherapy and surgery, 43 percent of the women who took vitamin D achieved a pathological complete response, meaning no cancer cells could be found in the breast tissue. In contrast, only 24 percent of the women who took the placebo reached that result. That is a near doubling of the rate of tumor eradication before surgery.
The researchers also measured blood levels of vitamin D in the participants. Women with levels above 20 nanograms per milliliter were more than three times as likely to achieve a complete tumor response, regardless of other clinical factors. This finding suggests that even moderate vitamin D sufficiency may help boost the effectiveness of chemotherapy.
Vitamin D modulates genes involved in cell growth, programmed cell death, and the prevention of tumor spread. It may also make cancer cells more sensitive to common chemotherapy drugs such as anthracyclines and taxanes. Earlier research has shown that vitamin D can enhance the tumor-killing effects of these drugs.
Many breast cancer patients, particularly those who are postmenopausal, have low vitamin D levels at the time of diagnosis. This deficiency may impair their response to treatment. Chemotherapy itself can further lower vitamin D levels because patients often have less sun exposure and the treatment affects metabolism. That makes supplementation during treatment a reasonable strategy.
The authors of the study noted that supplementing with a safe, accessible dose of vitamin D, such as 2,000 IU daily, during chemotherapy could be a simple way to improve treatment outcomes. While the trial was relatively small and conducted at a single center, its randomized design strengthens the evidence that vitamin D supplementation may help patients achieve better tumor control.
The researchers called for more studies to confirm these findings in diverse populations and to explore the best dosing. Because vitamin D is affordable and safe at recommended doses, it may be a practical addition to breast cancer treatment, especially for patients with low levels.
Vitamin D is best known for its role in bone health, but this study adds to a growing body of research linking nutrient status to cancer outcomes. Maintaining adequate vitamin D could be a low-risk way to support more successful breast cancer treatment.
